Infectious Disease Molecular Diagnostics Market Size Worth $40.8 Billion By 2028: Grand View Research, Inc.

 

The global infectious disease molecular diagnostics market size is expected to reach USD 40.8 billion by 2028, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 3.0% from 2020 to 2028. The market is driven by the introduction of technologically advanced products and an increase in demand for molecular diagnostics in PoC settings.

Key Insights & Findings:

• The reagent segment is expected to exhibit the fastest growth rate attributable to increased adoption
• The growing geriatric population in Asian countries, such as Japan and China, with high untapped opportunities is expected to drive the market for infectious disease molecular diagnostics in the region during the forecast period
• The In Situ Hybridization (ISH) segment is anticipated to witness the fastest growth rate owing to high sensitivity and lower complexity
• The high growth rate of the market for infectious disease molecular diagnostics in the Asia Pacific can be attributed to increased access to healthcare in the developing nations

Read 169 page market research report, “Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Technology (PCR, ISH, INAAT), By End-use, By Application, By Region, And Segment Forecasts, 2021 – 2028”, by Grand View Research

Rapid technological advancements with portability, accurate results, and cost-effectiveness are anticipated to serve as crucial drivers of the market for infectious disease molecular diagnostics. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Key players are updating their product portfolio for PCR instruments with increased R&D initiatives for developing novel kits to target emerging diseases or by entering into agreements with other kit manufacturing companies.

Technologies such as INAAT, mass spectroscopy, and ISH are advanced and have a low false-positive rate as compared to other traditional diagnostic tests. Advantages such as the cost-effectiveness and user-friendliness of this technology and the accuracy offered are estimated to increase the adoption of this technology.

The use of molecular diagnostics in research institutes is increasing. The use of techniques such as PCR, western blotting, and southern blotting is becoming common. Moreover, the spread of SARS-CoV-2 infection globally has led to an increase in research funding by governments as well as diagnostic companies to search for innovative molecular diagnostics.

Molecular diagnostics deliver effective and accurate results. Moreover, these tests enable the early detection of diseases, maintaining a low threat of substitutes. However, the high prices of these tests are expected to encourage patients to shift to external substitutes. Moreover, for the detection of newer infections such as SARS-CoV-2, the rate of internal substitution is high, which boosts competitive rivalry.

Grand View Research has segmented the global infectious disease molecular diagnostics market based on product, end use, technology, application, and region:

• Infectious Disease Molecular Diagnostics Product Outlook (Revenue, USD Million, 2017 – 2028)
  • Instruments
  • Reagents
  • Services
• Infectious Disease Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2017 – 2028)
  • Hospitals
  • Clinics
  • Diagnostics Laboratories
  • Research Institutes
• Infectious Disease Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2017 – 2028)
  • Polymerase Chain Reaction (PCR)
    • PCR, by Type
      • Multiplex PCR
      • Other PCR
    • PCR, by Product
      • Instruments
      • Reagents
      • Services
  • In Situ Hybridization
    • Instruments
    • Reagents
    • Services
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Instruments
    • Reagents
    • Services
  • Chips and Microarrays
    • Instruments
    • Reagents
    • Services
  • Mass Spectrometry
    • Instruments
    • Reagents
    • Services
  • Sequencing
    • Instruments
    • Reagents
    • Services
  • Transcription Mediated Amplification
    • Instruments
    • Reagents
    • Services
  • Others
    • Instruments
    • Reagents
    • Services
• Infectious Disease Molecular Diagnostics Application Outlook (Revenue, USD Million, 2017 – 2028)
  • Respiratory Diseases
  • Tuberculosis
  • Meningitis
  • Gastrointestinal Tract Infections
  • HPV
  • Sexually Transmitted Infections
  • Sepsis
  • Drug Resistance Diseases
  • Other Infectious Diseases
• Respiratory Diseases Outlook (Revenue, USD Million, 2017 – 2028)
  • Respiratory Diseases, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Respiratory Diseases, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Respiratory Diseases, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Tuberculosis Outlook (Revenue, USD Million, 2017 – 2028)
  • Tuberculosis, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Tuberculosis, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Tuberculosis, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Meningitis Outlook (Revenue, USD Million, 2017 – 2028)
  • Meningitis, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Meningitis, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Meningitis, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Gastrointestinal Tract Infections Outlook (Revenue, USD Million, 2017 – 2028)
  • Gastrointestinal Tract Infections, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Gastrointestinal Tract Infections, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Gastrointestinal Tract Infections, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• HPV Outlook (Revenue, USD Million, 2017 – 2028)
  • HPV, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • HPV, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • HPV, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Sexually Transmitted Infections Outlook (Revenue, USD Million, 2017 – 2028)
  • Sexually Transmitted Infections, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Sexually Transmitted Infections, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Sexually Transmitted Infections, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Sepsis Outlook (Revenue, USD Million, 2017 – 2028)
  • Sepsis, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Sepsis, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Sepsis, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Drug Resistance Disease Outlook (Revenue, USD Million, 2017 – 2028)
  • Drug Resistance Disease, By Product (Revenue, USD Million, 2017 – 2028)
    • Instruments
    • Reagents
    • Services
  • Drug Resistance Disease, By End Use (Revenue, USD Million, 2017 – 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Drug Resistance Disease, By Technology, (Number of Tests Performed from 2017 – 2028 in Million) (Revenue, USD Million, 2017 – 2028)
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
• Infectious Disease Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2017 – 2028)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

List of Key Players of Infectious Disease Molecular Diagnostics Market

• Abbott
• Becton, Dickinson and Company
• bioM√©rieux SA
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Danaher Corporation
• Hologic, Inc. (Gen-Probe)
• Illumina, Inc.
• Grifols S.A.
• Qiagen
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Sysmex Corporation

Check out more studies related to molecular diagnostics, conducted by Grand View Research:

• Molecular Diagnostics Market – The global molecular diagnostics market size was valued at USD 36.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.9% from 2021 to 2028. The growth can be attributed to technological advancements, rising elderly population, and external funding for R&D.
• Oncology based Molecular Diagnostics Market – Global oncology based molecular diagnostics market size was valued at USD 1,136.5 million in 2014 and is expected to grow at a CAGR of 14.7% over the forecast period. Rising prevalence of various types of cancer such as breast, colorectal, and Non-Small Cell Lung Cancer (NSCLC) amongst the world population is the key driver propelling the growth of oncology based molecular diagnostics industry.
• Point-of-Care Molecular Diagnostics Market – The global point-of-care molecular diagnostics market size was valued at USD 1.72 billion in 2018 and is anticipated to expand at a CAGR of 14.4% over the forecast period. Increased need for accurate and faster testing methods and results for the molecular tests is expected to propel the market growth.

Browse through Grand View Research’s coverage of the Global Clinical Diagnostics Industry.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports